1stOncology™: Cancer Intelligence Service – Page 18513 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Update

In May of 2013, Tamir received a decision from the SEC, revoking registration of the common stock of Tamir (Press release Tamir Biotechnology, FEB 5, 2014, View Source [SID:1234500377]). Broker-dealers have been prohibited from executing trades of Tamir common stock, and thus, public trading of Tamir’s stock ceased in early July of 2013. With a new management team in place, they are refocusing the science toward solving difficult antiviral problems (such as HPV and CMV). They believe in the potential efficacy of Onconase(r) for the treatment of viruses, so they continue work to obtain credible results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results

USA (2013); submitted Biologics License Application to the US FDA in 2013 (Press release Merck & Co, FEB 5, 2014, View Source [SID:1234500314]).

Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies

On February 5, 2014 Pfizer reported that it has agreed with Merck & Co to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets (Press release , FEB 5, 2014, View Source [SID:1234500283]). A Phase I/II clinical study will evaluate the safety and anti-cancer efficacy of MK-3475 combined with Pfizer’s axitinib. A separate Phase I study will evaluate the safety and tolerability of the combination of MK-3475 and PF-05082566 (PF-2566).
Pfizer will conduct the clinical studies of MK-3475 plus axitinib and MK-3475 plus PF-2566. This agreement does not provide for any collaboration between Pfizer and Merck following the completion of the specified studies.
Financial terms were not disclosed.
Under a separate agreement Pfizer and Merck are currently exploring the pre-clinical combination of MK-3475 with Pfizer’s investigational therapy palbociclib (PD-0332991). Merck is conducting these pre-clinical studies. Further studies would depend on the outcome of the ongoing pre-clinical studies as well as subsequent agreement by Merck and Pfizer.

(Press release, Bayer, FEB 4, 2014, View Source;parent=news-overview-category-search-en&ccm=800010 [SID:1234505761])

(Press release GW Pharmaceuticals, FEB 4, 2014, View Source [SID:1234501598])